Foghorn Therapeutics Inc. (FHTX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Foghorn Therapeutics Inc. (FHTX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

4.20

-0.17 (-3.89%)

At close: Jan 14, 2025, 3:59 PM

4.24

0.95%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	1.72
Market Cap	233.49M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.85
PE Ratio (ttm)	-2.27
Forward PE	n/a
Analyst	Buy

Ask	6
Volume	68,830
Avg. Volume (20D)	158,032
Open	4.43
Previous Close	4.37
Day's Range	4.13 - 4.46
52-Week Range	2.70 - 10.25
Beta	undefined

About FHTX

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 23, 2020

Employees 116

Stock Exchange NASDAQ

Ticker Symbol FHTX

Website https://foghorntx.com

Analyst Forecast

According to 5 analyst ratings, the average rating for FHTX stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 209.52% from the latest price.

Buy 80.00%

Hold 20.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Foghorn Therapeutics Inc. is scheduled to release its earnings on Mar 6, 2025, before market opens.
Analysts project revenue of $8.14M, reflecting a 41.10% YoY growth and earnings per share of -0.27, making a -52.63% decrease YoY.

Why Price Moved

1 month ago · Source

+3.96%

Foghorn Therapeutics shares rare trading lower aft... Unlock content with Pro Subscription

4 months ago · Source

+20.93%

Foghorn Therapeutics shares are trading higher after Evercore ISI Group initiated coverage on the stock with an Outperform rating and announced a $20 price target.

News

5 days ago · zacks.com

Foghorn Therapeutics (FHTX) Upgraded to Strong Buy: Here's What You Should Know

Foghorn Therapeutics (FHTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

1 month ago · zacks.com

After Plunging -30.17% in 4 Weeks, Here's Why the Trend Might Reverse for Foghorn Therapeutics (FHTX)

The heavy selling pressure might have exhausted for Foghorn Therapeutics (FHTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stree...

1 month ago · zacks.com

Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why

Foghorn Therapeutics (FHTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago · zacks.com

Wall Street Analysts See a 104.08% Upside in Foghorn Therapeutics (FHTX): Can the Stock Really Move This High?

The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 104.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ...

2 months ago · zacks.com

Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.34 per share a year ago.